EUSA, which is a global biopharmaceutical company announced on May 15 that they would be appointing Carsten Thiel as the president in Europe. The biopharmaceutical company focuses primarily on rare cancers and advancing in oncology, looking for new cancer treatments and medications to cure cancer once and for all. Carsten Thiel is one of the best candidates for his new senior leadership position on the team thanks to his two and a half decades of experience in the industry.
Before coming on board at EUSA, he was the CEO of the gene therapy specialist company, Abeona Therapeutics Inc. Before being the CEO of this prestigious company he was the Chief Commercial Officer at Alexion Pharmaceuticals, a company designed for finding medicine to cure rare diseases.
With Carsten Thiel as the President over EUSA in the Europe division, there is the possibility of taking the company to new levels that have yet to be seen. His twenty-seven years of experience in the industry makes him a leading expert in hematology, oncology and studying rare cancers and other diseases in order to develop new treatment plans that are are not yet available.
Doctor Carsten Thiel’s plan is to help grow EUSA’s business commercial infrastructure throughout Europe and take it to the next level so that it can have clinical development facilities located not only throughout Europe but on a global scale.
Doctor Thiel began his prestigious medical career in researching and finding cures for cancers and other rare diseases when he began his formal education. He gained his Ph.D. in Molecular Biology and his Ph.D. in biochemistry from the renowned university, the Max Planck Institute in Germany. It did not take long for him to put his formal education to use and start his long career in the Pharmaceutical industry in finding cures for cancer and other diseases.
For details: inspirery.com/carsten-thiel/